Enhanced Safety Surveillance of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany, and Spain During the 2022/2023 Influenza Season
- PMID: 38949714
- PMCID: PMC11485106
- DOI: 10.1007/s40264-024-01456-y
Enhanced Safety Surveillance of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany, and Spain During the 2022/2023 Influenza Season
Abstract
Background: Seasonal influenza is prevented through annual vaccination, especially in children and older adults. These vaccines are annually updated based on World Health Organization recommendations and require continuous safety monitoring.
Objective: We assessed the frequency and severity of adverse events within 7 days of administering GSK's inactivated quadrivalent seasonal influenza vaccine (IIV4) in Belgium, Germany, and Spain during the 2022/2023 influenza season.
Methods: In this enhanced safety surveillance study, adults who received GSK's IIV4 and parents/guardians/legally acceptable representatives of vaccinated children (aged 6 months-17 years) were invited to complete adverse drug reaction cards reporting adverse events within 7 days post-vaccination.
Results: In total, 1332 participants (53.6% female) received at least one dose of GSK's IIV4, including 43 children who received two doses. Overall, 97.8% of adverse drug reaction cards were completed and returned in the study. All participants in Belgium were adults, while 54.7% and 7.4% in Spain and Germany, respectively, were pediatric participants aged 6 months-17 years. After Dose 1, across all age groups, 49.8% of participants reported at least one adverse event. The most common adverse events (cumulative frequency >5%) following Dose 1 were injection-site pain (37.6%), fatigue (15.0%), headache (13.2%), injection-site swelling (9.3%), myalgia (7.6%), and injection-site erythema (7.4%). Across all countries, adverse events were most common in adults aged 18-65 years (59.7%), followed by those aged 3-17 years (47.0%), >65 years (35.7%), and 6-35 months (23.5%). After Dose 2, 18.6% of participants reported at least one adverse event, with general disorders and administration site conditions again being the most frequent.
Conclusions: Across all age and risk groups for serious disease, no serious adverse events related to GSK's IIV4 were reported within 7 days post-vaccination. This study supports and confirms the acceptable safety profile of GSK's IIV4 across all recommended age groups.
Clinical trial registration: ClinicalTrials.gov number: not applicable.
© 2024. GSK.
Conflict of interest statement
Carlos Brotons, Ignacio Salamanca, Tamara Eckermann, and Falko Panzer declare that their institution received payment from GSK for the conduct of the study. Xavier Martínez‐Gómez declares having received payment or honoraria for lectures, presentations, meetings, or educational events from AstraZeneca and Pfizer. Andrew Hastie, Jean-Yves Pirçon, Jennifer E. Gerber, Vanja Nikic, and Hannah Alsdurf were employees of the GSK group of companies. Andrew Hastie, Jean-Yves Pirçon, and Vanja Nikic possesses stock options in GSK. Paul Talsma was an employee of the GSK group of companies at the time of the study. The authors declare no other financial and non‐financial relationships and activities.
Figures
Similar articles
-
Safety Profile of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain: Passive Enhanced Safety Surveillance Study for the 2019/2020 Influenza Season.Drug Saf. 2021 Dec;44(12):1375-1390. doi: 10.1007/s40264-021-01121-8. Epub 2021 Oct 25. Drug Saf. 2021. PMID: 34694589 Free PMC article.
-
Brand-Specific Enhanced Safety Surveillance of GSK's Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain for the 2018/2019 Season.Drug Saf. 2020 Mar;43(3):265-279. doi: 10.1007/s40264-019-00893-4. Drug Saf. 2020. PMID: 31884676 Free PMC article.
-
Enhanced Safety Surveillance of GSK's Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany, and Spain for the 2018/19 Season: Interim Analysis.Adv Ther. 2019 Dec;36(12):3340-3355. doi: 10.1007/s12325-019-01105-2. Epub 2019 Oct 8. Adv Ther. 2019. PMID: 31595482 Free PMC article.
-
Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013-May 31, 2015.Vaccine. 2016 May 11;34(22):2507-12. doi: 10.1016/j.vaccine.2016.03.048. Epub 2016 Mar 23. Vaccine. 2016. PMID: 27015735 Free PMC article. Review.
-
High-Dose Inactivated Influenza Vaccine Quadrivalent for Older Adults.Ann Pharmacother. 2021 Jan;55(1):89-97. doi: 10.1177/1060028020935645. Epub 2020 Jun 24. Ann Pharmacother. 2021. PMID: 32578447 Review.
References
-
- World Health Organization (WHO). Influenza (seasonal). Available from: https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal). [Accessed 26 Sep 2023].
-
- European Centre for Disease Prevention and Control (ECDC). Factsheet about seasonal influenza. Available from: https://www.ecdc.europa.eu/en/seasonal-influenza/facts/factsheet. [Accessed 26 Sep 2023].
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical